Cell & Gene Therapy Drug Delivery Devices Market to grow at an Impressive CAGR During the Forecast Period
Rising awareness regarding the benefits of cell &
gene therapy is driving Global Cell & Gene Therapy Drug Delivery Devices
Market in forecast period.
According to TechSci
Research report, “Global Cell & Gene Therapy Drug Delivery Devices
Market By Type (Subretinal Injection Cannula, Extension
Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe,
Infusion Bags) By Commercialized Drugs (Luxturna,
Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) By Route of
Administration (Oral, Intravenous, Ocular, Transdermal, Others) By Method (In
Vitro v/s Ex Vivo) By Region, Competition Forecast & Opportunities, 2026”,
the global cell & gene therapy drug delivery devices market is projected to
grow with an anticipated CAGR in the upcoming five years. The market growth can
be attributed to rising number of patients suffering from chronic illness like
cancer, diabetes, and other genetic disorders. Government aids, and private
funds are strengthening the cell and gene therapy sector of healthcare
industry. The field involves multiple researches that are ongoing and is
directly influencing the growth of the global cell & gene therapy drug
devices market. Multiple technically advanced devices are being launched and
FDA is actively providing the approval for the usage of those devices thus, the
factor is main cause of the market growth in the next five years.
Moreover, the market is
experiencing a surge in demand of novel treatment development for rare
diseases, along with rising biopharmaceutical expenses on research and
development the market is anticipated to show its growth at the expected CAGR
in the forecast period, 2022-2026. Also, clinical trials and latest cell &
gene therapies are being conducted under the guidance of Food & Drug
Administration, which is also an important factor that drives the market growth
in the next five years.
Browse over XX market data Figures spread through 110 Pages
and an in-depth TOC on "Global Cell & Gene Therapy Drug Delivery
Devices Market"
https://www.techsciresearch.com/report/cell-and-gene-therapy-drug-delivery-devices-market/7364.html
Cell & gene therapy
involves extraction of cells, protein, and genetic material like DNA from the
donor which is then altered to provide the required result and thus a highly
personalized therapy. The genetic material like DNA in humans, carry genetic
information that translates into proteins that perform various functions in the
body. In the cell & gene therapy, the genetic material in extracted from
the cell and the DNA is altered using various methods of insertion, deletion,
replacement, etc. Now the altered DNA, multiplies and proteins are made, that
either is a treatment for the disease, or inhibits the proteins that are
causing the disease. The developmental research has devised drug delivery
system that are effective and long-lasting over traditional medicines.
The
global cell & gene therapy drug delivery devices market is segmented by type,
commercialized drugs, route of administration, method, regional distribution,
and competitional landscape. Based on commercialized drugs the market is
divided into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis.
Luxturna is anticipated to dominate the market since it is a prescription gene
therapy product that is used to treat inherited retinal diseases that is caused
due to mutations in the genetic material. Number of patients suffering from
retinal diseases are increasing at an alarming rate, thus the factor is
anticipated to support the expected growth of the sub-segment of the market in
upcoming five years. Kymriah, is a genetically modified, T-cell immunotherapy
drug that is for the treatment of patients aged 25 years, with B-cells
precursor acute lymphoblastic leukemia that is in a relapse stage. Provenge is
a prescription medicine genetically modified to treat advanced prostate cancer
in men. The genetically modified drugs are FDA approved and commercialized
thereby driving the market growth of global cell & gene therapy drug delivery
devices market in next five years by increasing the demand for these drug
deliveries.
Some of the major
competitors in the market are Becton, Dickinson, and Company, Novartis AG,
Amgen Inc., Kite Pharma, Inc., Pfizer, Inc., Bausch & Lomb Incorporated, Bluebird
bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.),
Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Orchard
Therapeutics plc, Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V.,
Vericel Corporation, among others. Top players have incorporated certain
strategies like partnerships and investments in the research and development of
the technically advanced products to excel their position in the competitive
landscape of the market.
Download Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=7364
Customers can also request for 10% free customization on this report.
“With an excellent
service in healthcare industry and its technologically sound sector North
American region is anticipated to dominate the market. Maximum number of top
players are present in the same region in large economy like United States, and
Canada. Also, the healthcare industry in these large economies possesses high
adoption rate of the advanced cell & gene therapy procedure that are
expected to drive the market growth. Top international players may seek
opportunities in the Asia Pacific market since the region is practically
untapped and the developing countries like India, China, are gaining awareness
about the novel systems,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based Global management consulting firm.
“Global Cell & Gene
Therapy Drug Delivery Devices Market By Type (Subretinal Injection Cannula,
Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled
Syringe, Infusion Bags) By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis) By Route of Administration (Oral, Intravenous,
Ocular, Transdermal, Others) By Method (In Vitro v/s Ex Vivo) By Region,
Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential
of global cell & gene therapy drug delivery devices and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global cell & gene therapy drug delivery devices.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/